In contrast, the combination of inetetamab with pyrotinib exhibited much stronger tumor growth inhibition with a TGI rate of approximately 72%, significantly better than that of the two anti-HER2 mAbs (trastuzumab and pertuzumab) combined (p < 0.05), suggesting that pyrotinib may induce a stronger synergistic antitumor effect when combined with inetetamab than that of the current standard of care (trastuzumab plus pertuzumab) (Figure 1a). The gene discussed is ERBB2; the disease is neoplasm.